 2020 is the latest installment of an annual series that documents antibody therapeutics approved in the US or EU, those in regulatory review, and those in late-stage clinical studies. As of November 2019, five novel antibody therapeutics had been granted a first approval in either the US or EU, and marketing applications were undergoing review for 13 other antibodies. Additionally, there were 79 antibodies undergoing evaluation in late-stage clinical studies, with 40 of them being treatments for cancer. The biopharmaceutical industry's pipeline of antibody therapeutics is robust and should provide a continuous supply of innovative products for. This article was authored by Helene Kaplan, Renalini Merlederan, Zeta Schneider, and others. We are article.tv, links in the description below.